vs
ClearPoint Neuro, Inc.（CLPT）与Digimarc CORP（DMRC）财务数据对比。点击上方公司名可切换其他公司
ClearPoint Neuro, Inc.的季度营收约是Digimarc CORP的1.2倍（$10.4M vs $8.9M），ClearPoint Neuro, Inc.同比增速更快（34.0% vs 2.9%），Digimarc CORP自由现金流更多（$895.0K vs $-12.1M），过去两年ClearPoint Neuro, Inc.的营收复合增速更高（16.7% vs -5.3%）
ClearPoint Neuro是一家专注于精准神经医学领域的医疗科技企业，研发和商业化微创脑部手术术中导航、精准靶向与递送系统，面向全球神经外科临床机构及中枢神经系统疗法研发的生物制药合作伙伴提供相关产品与服务。
迪吉马克公司是一家企业软件与服务提供商，其主打产品包含带数字标识符的软件，主要用于解决防伪问题、验证产品真伪、提升回收准确性以及实现供应链可追溯，产品可广泛应用于服装、快消品、美妆健康、汽车等多个行业领域。
CLPT vs DMRC — 直观对比
营收规模更大
CLPT
是对方的1.2倍
$8.9M
营收增速更快
CLPT
高出31.1%
2.9%
自由现金流更多
DMRC
多$13.0M
$-12.1M
两年增速更快
CLPT
近两年复合增速
-5.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $10.4M | $8.9M |
| 净利润 | — | $-4.2M |
| 毛利率 | 61.5% | 63.5% |
| 营业利润率 | -67.7% | -48.2% |
| 净利率 | — | -47.2% |
| 营收同比 | 34.0% | 2.9% |
| 净利润同比 | — | 51.4% |
| 每股收益（稀释后） | $-0.26 | $-0.18 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLPTDMRC
| Q4 25 | $10.4M | $8.9M | ||
| Q3 25 | $8.9M | $7.6M | ||
| Q2 25 | $9.2M | $8.0M | ||
| Q1 25 | $8.5M | $9.4M | ||
| Q4 24 | $7.8M | $8.7M | ||
| Q3 24 | $8.1M | $9.4M | ||
| Q2 24 | $7.9M | $10.4M | ||
| Q1 24 | $7.6M | $9.9M |
净利润CLPTDMRC
| Q4 25 | — | $-4.2M | ||
| Q3 25 | $-5.9M | $-8.2M | ||
| Q2 25 | $-5.8M | $-8.2M | ||
| Q1 25 | $-6.0M | $-11.7M | ||
| Q4 24 | — | $-8.6M | ||
| Q3 24 | $-5.0M | $-10.8M | ||
| Q2 24 | $-4.4M | $-9.3M | ||
| Q1 24 | $-4.1M | $-10.3M |
毛利率CLPTDMRC
| Q4 25 | 61.5% | 63.5% | ||
| Q3 25 | 63.2% | 58.3% | ||
| Q2 25 | 60.3% | 58.8% | ||
| Q1 25 | 60.5% | 65.0% | ||
| Q4 24 | 61.3% | 60.8% | ||
| Q3 24 | 59.7% | 62.4% | ||
| Q2 24 | 63.5% | 66.1% | ||
| Q1 24 | 59.2% | 62.5% |
营业利润率CLPTDMRC
| Q4 25 | -67.7% | -48.2% | ||
| Q3 25 | -59.5% | -109.7% | ||
| Q2 25 | -61.6% | -105.2% | ||
| Q1 25 | -72.6% | -128.9% | ||
| Q4 24 | -72.5% | -105.1% | ||
| Q3 24 | -63.5% | -120.4% | ||
| Q2 24 | -60.1% | -96.2% | ||
| Q1 24 | -55.2% | -109.2% |
净利率CLPTDMRC
| Q4 25 | — | -47.2% | ||
| Q3 25 | -66.5% | -106.9% | ||
| Q2 25 | -63.3% | -102.6% | ||
| Q1 25 | -71.0% | -125.2% | ||
| Q4 24 | — | -99.9% | ||
| Q3 24 | -61.2% | -113.9% | ||
| Q2 24 | -56.1% | -89.3% | ||
| Q1 24 | -54.3% | -104.0% |
每股收益（稀释后）CLPTDMRC
| Q4 25 | $-0.26 | $-0.18 | ||
| Q3 25 | $-0.21 | $-0.38 | ||
| Q2 25 | $-0.21 | $-0.38 | ||
| Q1 25 | $-0.22 | $-0.55 | ||
| Q4 24 | $-0.20 | $-0.40 | ||
| Q3 24 | $-0.18 | $-0.50 | ||
| Q2 24 | $-0.16 | $-0.43 | ||
| Q1 24 | $-0.16 | $-0.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $45.9M | $12.9M |
| 总债务越低越好 | $49.1M | — |
| 股东权益账面价值 | $28.0M | $40.2M |
| 总资产 | $97.7M | $53.0M |
| 负债/权益比越低杠杆越低 | 1.75× | — |
8季度趋势，按日历期对齐
现金及短期投资CLPTDMRC
| Q4 25 | $45.9M | $12.9M | ||
| Q3 25 | $38.2M | $12.6M | ||
| Q2 25 | $41.5M | $16.1M | ||
| Q1 25 | $12.4M | $21.6M | ||
| Q4 24 | $20.1M | $28.7M | ||
| Q3 24 | $21.6M | $33.7M | ||
| Q2 24 | $32.8M | $41.5M | ||
| Q1 24 | $35.4M | $48.9M |
总债务CLPTDMRC
| Q4 25 | $49.1M | — | ||
| Q3 25 | $29.2M | — | ||
| Q2 25 | $28.8M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $10.0M | — | ||
| Q1 24 | $10.0M | — |
股东权益CLPTDMRC
| Q4 25 | $28.0M | $40.2M | ||
| Q3 25 | $15.9M | $41.4M | ||
| Q2 25 | $19.7M | $46.5M | ||
| Q1 25 | $20.0M | $50.0M | ||
| Q4 24 | $25.4M | $61.4M | ||
| Q3 24 | $29.0M | $70.2M | ||
| Q2 24 | $32.1M | $77.2M | ||
| Q1 24 | $34.6M | $84.5M |
总资产CLPTDMRC
| Q4 25 | $97.7M | $53.0M | ||
| Q3 25 | $60.4M | $55.4M | ||
| Q2 25 | $62.9M | $60.7M | ||
| Q1 25 | $30.1M | $66.5M | ||
| Q4 24 | $39.2M | $75.8M | ||
| Q3 24 | $40.2M | $85.0M | ||
| Q2 24 | $52.6M | $93.4M | ||
| Q1 24 | $53.6M | $99.7M |
负债/权益比CLPTDMRC
| Q4 25 | 1.75× | — | ||
| Q3 25 | 1.84× | — | ||
| Q2 25 | 1.46× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.31× | — | ||
| Q1 24 | 0.29× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-12.1M | $991.0K |
| 自由现金流经营现金流 - 资本支出 | $-12.1M | $895.0K |
| 自由现金流率自由现金流/营收 | -116.5% | 10.0% |
| 资本支出强度资本支出/营收 | 0.5% | 1.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-24.4M | $-12.3M |
8季度趋势，按日历期对齐
经营现金流CLPTDMRC
| Q4 25 | $-12.1M | $991.0K | ||
| Q3 25 | $-3.1M | $-2.6M | ||
| Q2 25 | $-2.6M | $-4.7M | ||
| Q1 25 | $-6.2M | $-5.5M | ||
| Q4 24 | $-1.2M | $-4.2M | ||
| Q3 24 | $-1.2M | $-7.1M | ||
| Q2 24 | $-2.7M | $-6.8M | ||
| Q1 24 | $-3.8M | $-8.4M |
自由现金流CLPTDMRC
| Q4 25 | $-12.1M | $895.0K | ||
| Q3 25 | $-3.3M | $-2.8M | ||
| Q2 25 | $-2.6M | $-4.9M | ||
| Q1 25 | $-6.4M | $-5.5M | ||
| Q4 24 | $-1.5M | $-4.2M | ||
| Q3 24 | $-1.2M | $-7.2M | ||
| Q2 24 | — | $-6.9M | ||
| Q1 24 | — | $-8.5M |
自由现金流率CLPTDMRC
| Q4 25 | -116.5% | 10.0% | ||
| Q3 25 | -37.5% | -36.9% | ||
| Q2 25 | -28.7% | -61.0% | ||
| Q1 25 | -74.9% | -59.1% | ||
| Q4 24 | -19.4% | -49.1% | ||
| Q3 24 | -14.9% | -75.7% | ||
| Q2 24 | — | -66.1% | ||
| Q1 24 | — | -85.8% |
资本支出强度CLPTDMRC
| Q4 25 | 0.5% | 1.1% | ||
| Q3 25 | 2.2% | 2.9% | ||
| Q2 25 | 1.0% | 2.5% | ||
| Q1 25 | 2.2% | 0.6% | ||
| Q4 24 | 3.4% | 0.2% | ||
| Q3 24 | 0.1% | 0.7% | ||
| Q2 24 | 0.0% | 0.3% | ||
| Q1 24 | 0.0% | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLPT
| Neurosurgery Navigation And Therapy Disposable Products | $4.7M | 45% |
| Biologics And Drug Delivery Services And License Fees | $2.8M | 27% |
| Biologics And Drug Delivery Disposable Products | $2.4M | 23% |
| Other | $502.0K | 5% |
DMRC
| Subscription | $5.3M | 60% |
| The Government | $3.6M | 41% |
